In India’s fast-evolving wellness landscape, trust is becoming the real differentiator.
Hyderabad-based nutraceutical brand ZeroHarm Sciences has raised Rs 65 crore ($7.15 million) in a Series A funding round to double down on science-backed, plant-based preventive healthcare. The round saw Rs 40 crore invested by Kotak Alternate Asset Managers Limited through its Kotak Life Sciences Fund I, and Rs 25 crore from Alkemi Growth Capital.
For founders Sachin and Shweta Darbarwar, the raise is not just about expansion capital — it’s about accelerating a larger vision: building what they call India’s first “Trust over Promise” health platform.
Where Ayurveda Meets Nano Technology
Founded in 2020, ZeroHarm Sciences operates at the intersection of traditional wisdom and advanced science.
The company develops plant-based nutraceuticals using proprietary nano-formulation technology. By converting plant-derived nutrients into nano-sized particles, ZeroHarm enhances bioavailability and enables controlled release at lower dosages — a critical factor in improving supplement efficacy.
In simple terms, the body absorbs more of what actually matters.
Its formulations integrate Ayurveda with modern delivery systems, aiming to create preventive wellness solutions that go beyond marketing claims and focus on measurable health outcomes.
Controlling the Value Chain
One of the company’s defining strengths lies in its supply chain.
ZeroHarm works with a network of over 10,000 farmers across Northeast India and the Himalayan region for medicinal plant sourcing. By controlling the value chain — from cultivation to nano-processing — the brand aims to ensure consistency, traceability, and quality.
The company has also filed and received patents for multiple nano formulations, including:
-
Turmeric-based phytochemicals
-
Iron folic acid combinations
-
Carotenoid-based eye health solutions
-
Synbiotic gut health compositions
This IP-driven approach positions the company beyond a conventional D2C supplement brand.
Scaling in a Booming Market
ZeroHarm currently offers over 60 SKUs across categories such as diabetes management, heart health, joint care, immunity, gut health, oncology support, women’s wellness, and performance nutrition.
Its products are available through its website, as well as marketplaces like Amazon and Flipkart, along with quick commerce platforms. To date, the brand says it has served more than 300,000 customers.
The timing aligns with strong macro tailwinds. India’s nutraceutical market is projected to reach $18 billion by 2025, while the global market is expected to cross $720 billion by 2027 — reflecting a clear consumer shift toward preventive healthcare.
In this competitive space, ZeroHarm faces established and emerging players such as Kapiva, Plix, HealthKart, and Wellbeing Nutrition.
The Road Ahead
With fresh capital in hand, ZeroHarm plans to focus on national brand building, expand internationally across the USA, the UK, and the Middle East, and scale its research and manufacturing capabilities.
For Sachin and Shweta Darbarwar, the ambition is clear: move the nutraceutical conversation from claims to clinically demonstrated outcomes.
As Indian consumers grow more informed and outcome-driven, brands that combine science, transparency, and supply-chain control may define the next phase of the country’s preventive health movement.
-By Muskan Dengra
